Related Experiment Video
Updated: Jun 22, 2026
06:43
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
[Gastrointestinal stromal tumour: our experience]
Antonino Versaci1, Antonio Macrì, Antonio Ieni
1Istituto di Chirurgia d'Urgenza e dei Trapianti di Organo, Università degli Studi di Messina.
Chirurgia Italiana
|June 20, 2009
Summary
Gastrointestinal stromal tumors (GISTs) are common mesenchymal neoplasms. Surgical management combined with imatinib mesylate is the gold standard therapy for advanced GIST, particularly with metastases.
Area of Science:
- Gastroenterology
- Oncology
- Surgical Pathology
Context:
- Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal neoplasms in the GI tract.
- Originating from Cajal interstitial cells, GISTs commonly occur in the stomach and small intestine, predominantly in males aged 50-60.
- Non-specific symptoms and diagnostic challenges often lead to delayed detection, sometimes presenting as unexpected surgical findings or emergencies.
Purpose:
- To evaluate the outcomes of surgical and adjuvant therapies for GIST patients.
- To assess the efficacy of imatinib mesylate in advanced GIST cases.
Summary:
- Fifteen patients with GIST (gastric, ileal, jejunal, colonic) underwent surgery, with 9 receiving adjuvant therapy (4 chemotherapy, 5 imatinib mesylate).
- Mean follow-up was 38 months; no postoperative mortality and 13.3% morbidity were observed.
- Histological analysis revealed 6 benign and 9 malignant GISTs. Patients treated with imatinib mesylate showed a mean survival of 36 months.
Impact:
- Surgical management and imatinib mesylate represent the current gold standard for GIST treatment.
- Imatinib mesylate is recommended for advanced GIST, especially with liver and peritoneal metastases.
- This study highlights the effectiveness of combined surgical and imatinib therapy in improving outcomes for GIST patients.